Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: A systematic review

American Journal of Nephrology

Volumn 39, Issue 4, 2014, Pages 322-330

  Kronbichler, Andreas ^a   Kerschbaum, Julia ^a   Fernandez Fresnedo, Gema ^b   Hoxha, Elion ^c   Kurschat, Christine E ^d   Busch, Martin ^e   Bruchfeld, Annette ^f   Mayer, Gert ^a   Rudnicki, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hospital Marques de Valdecilla   (Spain)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Focal segmental glomerulosclerosis; Minimal change disease; Rituximab; Steroid dependent nephrotic syndrome

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEVAMISOLE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEFLOXACIN; RITUXIMAB; SERUM ALBUMIN; STEROID; TACROLIMUS; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

APHERESIS; ARTICLE; BRADYCARDIA; BRONCHOPNEUMONIA; CHEST TIGHTNESS; COUGHING; DRUG EFFICACY; DRUG ERUPTION; EMBASE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HICCUP; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; KIDNEY FUNCTION; LEUKOPENIA; MEDLINE; META ANALYSIS (TOPIC); MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OCULAR PRURITUS; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RELAPSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; MINIMAL CHANGE DISEASE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; NEPHROSIS, LIPOID;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; NEPHROSIS, LIPOID; RECURRENCE;

EID: 84898672361     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000360908     Document Type: Article

References (55)

1. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G: Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2: 445-453
2. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ: Focal segmental glomerulosclerosis in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15: 2169-2177
3. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068
4. Moghadam-Kia S, Werth VP: Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010; 49: 239-248
5. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80: 868-878
6. Westhoff TH, Schmidt S, Zidek W, Beige J, Van Der Giet M: Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006; 65: 393-400
7. Boyer O, Moulder JK, Grandin L, Somers MJ: Short-And long-Term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 2008; 23: 575-580
8. Sumegi V, Haszon I, Bereczki C, Papp F, Turi S: Long-Term follow-up after cyclophosphamide and cyclosporine-A therapy in steroiddependent and-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23: 1085-1092
9. Ueda N, Takahashi K, Akioka Y, Morooka M, Ogawa A, Tsuzuki K: Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome. J Nephrol 2009; 22: 610-615
10. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, Group RT: Rituximab for rheumatoid arthritis refractory to anti-Tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806
11. Cartin-Ceba R, Fervenza FC, Specks U: Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab. Curr Opin Rheum 2012; 24: 15-23
12. Kronbichler A, Mayer G: Renal involvement in autoimmune connective tissue diseases. BMC Med 2013; 11: 95
13. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasa M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425
14. Datta SK: Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol 2009; 5: 80-82
15. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46
16. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dotsch J: Long-Term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915
17. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A: Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: Multicentric report. Clin J Am Soc Nephrol 2010; 5: 2207-2212
18. Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K: Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25: 461-468
19. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K: Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2013; 28: 257-264
20. Hoxha E, Stahl RA, Harendza S: Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011; 76: 151-158
21. Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE: Rituximab treatment for adults with refractory nephrotic syndrome: A singlecenter experience and review of the literature. Nephron Clin Pract 2012; 120:c79-c85
22. Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, Egido J, Praga M; Trabajo De Enfermedades Glomerulares De La Sociedad Espanola De N: Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 1317-1323
23. Kodner C: Nephrotic syndrome in adults: Diagnosis and management. Am Fam Physician 2009; 80: 1129-1134
24. Teeninga N, Kist-van Holthe JE, Van Rijswijk N, De Mos NI, Hop WC, Wetzels JF, Van Der Heijden AJ, Nauta J: Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 2013; 24: 149-159
25. Hofstra JM, Deegens JK, Wetzels JF: Rituximab: Effective treatment for severe steroiddependent minimal change nephrotic syndrome?. Nephrol Dial Transplant 2007; 22: 2100-2102
26. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K: Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009; 72: 69-72
27. Amemiya N, Takei T, Kojima C, Nokiba H, Itabashi M, Nitta K: Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol 2011; 15: 933-936
28. Peters HP, Van De Kar NC, Wetzels JF: Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth J Med 2008; 66: 408-415
29. Yang T, Nast CC, Vo A, Jordan SC: Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 2008; 23: 377-380
30. François H, Daugas E, Bensman A, Ronco P: Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis 2007; 49: 158-161
31. Beco A, Castro-Ferreira I, Coentrao L, Neto R, Sampaio S, Pestana M: Rituximab for steroid-dependent nephrotic syndrome. Clin Nephrol 2010; 74: 308-310
32. Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, Itabashi M, Tsukada M, Takei T, Ogawa T, Yoshida T, Uchida K, Tsuchiya K, Nitta K: Successful use of singledose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009; 48: 1901-1904
33. Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, Shimizu A, Shiohira S, Moriyama T, Itabashi M, Mochizuki T, Uchida K, Tsuchiya K, Hattori M, Nitta K: Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012; 51: 759-762
34. Kronbichler A, Konig P, Busch M, Wolf G, Mayer G, Rudnicki M: Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: A report of 5 cases. Wien Klin Wochenschr 2013; 125: 328-333
35. Kong WY, Swaminathan R, Irish A: Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 2013; 45: 795-802
36. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschenes G, Ronco PM, Plaisier EM, Dahan KY: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83: 511-516
37. Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dialysis Transplant 2013; 28: 1225-1232
38. Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M: Rituximab for minimal change disease in adults: Long-Term follow-up. Nephrol Dial Transplant 2013, Epub ahead of print
39. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB: Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 2006; 21: 344-349
40. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2: 932-937
41. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative G: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010; 5: 2188-2198
42. Jones JD, Hamilton BJ, Rigby WF: Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum 2012; 64: 3111-3118
43. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F: Rituximab treatment for severe steroidor cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
44. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, Deschenes G, Ulinski T: Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after cd19 recovery. Nephrol Dial Transplant 2012; 27: 1083-1089
45. El-Reshaid K, Sallam HT, Hakim AA, Al-Attiyah R: Rituximab in treatment of idiopathic glomerulopathy. Saudi J Kidney Dis Transpl 2012; 23: 973-978
46. Wolach O, Shpilberg O, Lahav M: Neutropenia after rituximab treatment: New insights on a late complication. Curr Opin Hematol 2012; 19: 32-38
47. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL: Monoclonal antibody-Associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824
48. Bitzan M, Anselmo M, Carpineta L: Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. Pediatr Pulmonol 2009; 44: 922-934
49. Delbe-Bertin L, Aoun B, Tudorache E, Lapillone H, Ulinski T: Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?. Pediatr Nephrol 2013; 28: 447-451
50. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X: Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62: 2625-2632
51. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K: Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 2013; 28: 145-149
52. Wendt M, Gunnarsson I, Bratt J, Bruchfeld A: Rituximab in relapsing or refractory ANCAassociated vasculitis: A case series of 16 patients. Scand J Rheumatol 2012; 41: 116-119
53. Sakai K, Morito N, Usui J, Hagiwara M, Hiwatashi A, Fukuda K, Nanmoku T, Toda T, Matsui N, Nagata M, Yamagata K: Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. Nephrol Dial Transplant 2011; 26: 371-373
54. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; Group R-IR: Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010; 363: 221-232
55. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA: Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-776